TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/17/2025
Back to search
Official data from USPTO
ACCORD BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ACCORD BIOPHARMA
ST13
US500000097298517Class
5, 44
Filing
97298517
Registration
7592997
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
02/21/2025
Trademark type
Word
Nice classes
5, 44
Filing date
03/07/2022
Registration date
12/10/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/10/2024
Last transaction
02/21/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
11/19/2019
First use in commerce
11/19/2019
Drawing code
4
Owner type
03
Owner location
Durham, NC
Examiner
WLODARCZYK, CAROLYN
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Accord BioPharma, Inc.
Representatives
Michele K. Robichaux ODIN LAW AND MEDIA
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
A full line of medicated and pharmaceutical preparationspharmaceutical preparations and substances for use in the preventiontreatment and management of cancerautoimmune diseasesimmunological deficiency syndromes in the nature of autoimmune diseasescritical illnesses in the nature of immune system related diseases and disorders for use in connection with humans
Class 44
Providing healthcare and medical information; Providing information in the fields of OncologyImmunologyCritical Care
Publications
History of USPTO decisions and trademark events.
34 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/17/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/17/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/10/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/10/2024
PUBO
PUBLISHED FOR OPPOSITION
09/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/21/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/06/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/03/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/03/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/03/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
02/01/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
02/01/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/08/2023
GNFR
FINAL REFUSAL E-MAILED
11/08/2023
CNFR
FINAL REFUSAL WRITTEN
11/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/28/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/27/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
09/27/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/24/2023
GNSL
LETTER OF SUSPENSION E-MAILED
05/24/2023
CNSL
SUSPENSION LETTER WRITTEN
05/24/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/19/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/19/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/19/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
04/03/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
04/03/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/05/2023
GNRT
NON-FINAL ACTION E-MAILED
01/05/2023
CNRT
NON-FINAL ACTION WRITTEN
01/05/2023
DOCK
ASSIGNED TO EXAMINER
12/17/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/11/2022
NWAP
NEW APPLICATION ENTERED
03/10/2022
Continuous trademark protection
Get notified about every new filing that threatens ACCORD BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.